Trying to learn how to translate from the human translation examples.
From professional translators, enterprises, web pages and freely available translation repositories.
Üks ml suspensiooni sisaldab 10 mg tsütarabiini.
one ml of suspension contains 10 mg cytarabine.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Üks 5 ml viaal sisaldab 50 mg tsütarabiini
each 5 ml vial contains 50 mg cytarabine
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
tsütarabiini on kasutatud vähiravimina alates 1970. aastatest.
cytarabine has been used as an anti-cancer medicine since the 1970s.
Last Update: 2012-04-11
Usage Frequency: 2
Quality:
- toimeaine on 50 mg tsütarabiini (10 mg/ ml)
- the active substance is 50 mg cytarabine (10 mg/ ml)
Last Update: 2012-04-11
Usage Frequency: 2
Quality:
depocyte on süstesuspensioon, mis sisaldab toimeainena 50 mg tsütarabiini.
depocyte is a suspension for injection that contains 50 mg of the active substance, cytarabine.
Last Update: 2017-04-26
Usage Frequency: 5
Quality:
Üks viaal sisaldab 50 mg tsütarabiini (10 mg/ml).
each vial contains 50 mg cytarabine (10 mg/ml).
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
depocyte sisaldab tsütarabiini ja tuleb kõrvaldada vastavalt kohalikele nõuetele.
depocyte contains cytarabine, and should be disposed of in a manner consistent with local requirements.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
harva on vaba tsütarabiini intravenoosse manustamise järgselt teatatud anafülaktilistest reaktsioonidest.
anaphylactic reactions following intravenous administration of free cytarabine have been rarely reported.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
depocyte intratekaalsel manustamisel on süsteemsesse vereringesse jõudev tsütarabiini kogus kaduvväike.
the systemic exposure to free cytarabine following intrathecal treatment with depocyte was negligible.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
tsütarabiini inkorporeerimisega dna ja rna koostisse võib samuti selgitada ravimi tsütotoksilisi toimeid.
incorporation into dna and rna may also contribute to cytarabine cytotoxicity.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
kui tsütarabiini manustatakse intratekaalselt koos teiste tsütotoksiliste ainetega, võib suureneda neurotoksilisuse oht.
intrathecal co-administration of cytarabine with other cytotoxic agents may increase the risk of neurotoxicity.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
depocyte on toimeainet pidevalt vabastav tsütarabiini ravimvorm, mis on mõeldud tserebrospinaalvedelikku manustamiseks.
depocyte is a sustained-release formulation of cytarabine, designed for direct administration into the cerebrospinal fluid (csf).
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
tsütarabiini kliirens tserebrospinaalvedelikust on sarnane tserebrospinaalvedeliku totaalsele äravoolukiirusele, mis on 0,24 ml/min.
the csf clearance rate of cytarabine is similar to the csf bulk flow rate of 0.24 ml/min.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
on leitud, et depocyte 50 mg ja 75 mg intratekaalsel manustamisel on tsütarabiini jõudmine süsteemsesse vereringesse väga vähene.
systemic exposure to cytarabine was determined to be negligible following intrathecal administration of 50 mg and 75 mg of depocyte.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
need muutused arvatakse olevat sarnased teiste ainete, sh ka kapseldamata tsütarabiini intratekaalsel manustamisel esinevate toksiliste toimetega.
these changes were believed to be consistent with the toxic effects of other intrathecal agents such as unencapsulated cytarabine.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
uuringus näidati samuti, et paljude soliidtuumorite rakud olid tsütarabiinile tundlikud, seda eriti pärast pikaajalisemaid tsütarabiini ekspositsioone.
the studies also demonstrated susceptibility of many solid tumour cell lines to cytarabine, particularly after longer periods of exposure to cytarabine.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
tsütarabiini intravenoossel manustamisel tekivad süsteemse toksilisuse nähud, mis avalduvad peamiselt luuüdi pärssumise ning leukopeenia, trombotsütopeenia ja aneemiana.
systemic toxicity due to intravenous administration of cytarabine consists primarily of bone marrow suppression with leucopenia, thrombocytopenia and anaemia.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
rohkem kui 90% tsütarabiini eritus 4. päevaks, millele lisandus 21. päevaks veel 2,7%.
more than 90% of cytarabine was excreted by day 4 and an additional 2.7% by 21 days.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
tsütarabiini ja lipiidiosakeste peamise, fosfolipiidse komponendi (dopc) jaotumist ja kliirensit uuriti närilistel pärast depocyte intratekaalset manustamist.
the distribution and clearance of cytarabine and of the predominant phospholipid component of the lipid particle (dopc) following intrathecal administration of depocyte was evaluated in rodents.
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
tsütarabiini transport liikvorist plasmasse toimub aeglaselt ning konversioon inaktiivseks metaboliidiks uratsiilarabinosiidiks (ara-u) toimub plasmas kiiresti.
the transfer rate of cytarabine from csf to plasma is slow and the conversion to uracil arabinoside (ara-u), the inactive metabolite, in the plasma is fast.
Last Update: 2017-04-26
Usage Frequency: 3
Quality: